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Anticoagulation can be achieved by inhibition of the various 
coagulation factors. Non-VKA oral anticoagulant (NOAC) 
development has focused on the synthesis of selective inhibi-
tors of coagulation factors, preferably acting independently 
of cofactors. The NOACs act on a number of targets in the 
coagulation cascade, but two of its key factors, Xa and IIa 
(thrombin), are the major therapeutic targets. As they are 
involved in the final steps of the coagulation cascade, their 
inhibition allows blocking of both intrinsic and extrinsic 
coagulation pathways.
As the serine protease thrombin is the final mediator in 
the coagulation cascade that leads to the production of fibrin, 
is the main protein component of blood clots [1], and is also 
a potent activator of platelets, it has been a popular target for 
the development of novel anticoagulants [2]. Several direct 
thrombin inhibitors (DTIs) have been approved for clinical 
use in the prevention of thrombosis, for example desirudin. 
However, those agents that still require parenteral adminis-
tration are not suitable for, ichronic use, and the need for 
development of efficient, safe, convenient, and predictable 
oral anticoagulants led to development of oral agents.
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82.1  Historical Excursus: Ximelagatran
Ximelagatran, a prodrug of melagatran, was the first oral 
DTI used in clinical trials from 1999. Its reproducible 
 pharmacokinetic characteristics, rapid onset of action and 
relatively few interactions with food and other drugs raised 
hopes that it would allow effective oral anticoagulation 
 without the need for regular INR monitoring. Advanced 
phase III clinical trials proved ximelagatran to be a potent 
anticoagulant with ability to prevent venous thromboembo-
lism (VTE) at least as efficiently as injections of the 
low-molecular-weight heparin (LMWH) enoxaparin  followed 
by administration of warfarin [3]. Ximelagatran was also 
found to be safe in terms of risk of hemorrhage. However, the 
randomized, double-blind Thrombin Inhibitor in Venous 
Thromboembolism Treatment (THRIVE) trial and further 
studies revealed that treatment with ximelagatran carried 
substantial risk of hepatotoxicity [4].
On the basis of health concerns ximelagatran did not 
receive Food and Drug Administration (FDA) approval and 
it was subsequently withdrawn by AstraZeneca following 
the EXTEND study because of fear of liver toxicity [5]. The 
EXTEND study was terminated due to a case of severe 
acute liver injury just 3 weeks after completion of the 
35-day course of treatment. Even though ximelagatran has 
been discontinued, it is very important for practitioners to 
know this information since safety issues of NOACs are still 
a major concern.
2.2  Dabigatran Etexilate
Dabigatran is a potent nonpeptide DTI but it is not orally 
active and so its physicochemical characteristics were modi-
fied to produce a prodrug, dabigatran etexilate (Fig. 2.1). This 
differs from dabigatran by an ethyl group at the carboxylic 
acid and a hexyloxycarbonyl side chain at the amidine, and it 
has strong and long-lasting anticoagulant effects after oral 
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9administration [6]. Dabigatran etexilate possesses a number 
of qualities that make it an attractive anticoagulant. It has 
rapid absorption (onset of action within 2 h) and its half-life 
is approximately 8 h after single-dose administration and up 
to 14–17 h after multiple doses (Table 2.1) [7].
Dabigatran etexilate is a double prodrug that is converted 
by esterases into its active metabolite, dabigatran, once it has 
been absorbed from the gastrointestinal tract. As bioconver-
sion of dabigatran etexilate to dabigatran begins in the gut, 
the drug enters the portal vein as a combination of prodrug 
and active compound.
The cytochrome P450 system plays no part in the metabo-
lism of dabigatran etexilate; therefore, the risk of drug inter-
actions is low. Because the bioavailability of dabigatran 
etexilate is only 6.5 %, relatively high doses of the drug must 
be given to ensure that adequate plasma concentrations are 
achieved [8]. The absorption of dabigatran etexilate in the 
stomach and small intestine is dependent on an acid environ-
ment. To promote such a microenvironment, dabigatran 
etexilate is provided in tartaric acid-containing capsules. 
Absorption is reduced by 20–25 % if patients are concur-
rently on proton pump inhibitors [14]. Once it reaches the 
liver, bioconversion of the prodrug is completed, and 
 approximately 20 % is conjugated and excreted via the bili-
ary system. Approximately 80 % of circulated dabigatran is 
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Figure 2.1 Dabigatran etexilate
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excreted unchanged via the kidneys. Consequently, plasma 
concentrations increase in patients with renal insufficiency. It 
is contraindicated in patients with severe renal failure.
It is noteworthy that dabigatran etexilate has no known 
interactions with food, as well as having a low potential for 
drug interactions [2]. Accumulated evidence from completed 
and ongoing trials confirms the hepatic safety of the drug [15].
Dabigatran etexilate has been evaluated in a number of 
phase II and phase III studies in several disorders (Table 2.2).
2.2.1  Venous Thromboembolism Prevention 
in Major Orthopedic Surgery
Clinical evaluation of dabigatran etexilate started in the set-
ting of major joint surgery. In the multicenter, open-label, 
phase II BISTRO I trial [16], 314 patients undergoing total 
hip replacement (THR) were assigned to receive different 
doses of dabigatran etexilate (12.5, 25, 50, 100, 150, 200, or 
300 mg twice daily (bid), or 150 or 300 mg qd) administered 
4–8 h after surgery for 6–10 days. No major hemorrhages 
were observed in any group. However, non-major multiple- 
site hemorrhage was observed in two patients with reduced 
renal clearance treated with the highest dose (300 mg bid). 
The overall incidence of deep vein thrombosis (DVT) was 
12.4 %, without a consistent relationship between incidence 
and dose. The lowest dose (12.5 mg bid) showed a high rate 
of proximal DVT (12.5 %).
In the subsequent phase II BISTRO II trial [17] the 1973 
patients undergoing THR or total knee replacement (TKR) 
were randomized to 6–10 days of dabigatran etexilate (50, 
150, or 225 mg bid, or 300 mg qd) starting 1–4 h after surgery, 
or enoxaparin (40 mg qd) starting 12 h prior to surgery. VTE 
occurred in 28.5, 17.4, 13.1, 16.6, and 24 % of patients assigned 
to dabigatran etexilate 50, 150, 225 mg bid, 300 mg qd, and 
enoxaparin, respectively. Compared with enoxaparin, VTE 
was significantly lower in patients receiving 150 or 225 mg bid 
or 300 mg qd, and major hemorrhage was significantly lower 
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Table 2.2 Clinical development program for dabigatran etexilate
Clinical condition Trial Comparator (n)
VTE prevention in 
major joint surgery
Phase II
BISTRO I [16] No comparator (314)
BISTRO II [17] Enoxaparin (1973)
Phase III
RE-MODEL [18] Enoxaparin (2076)
RE-NOVATE [19] Enoxaparin (3494)
RE-MOBILZE [20] Enoxaparin (1896)
RE-NOVATE II [21] Enoxaparin (1920)
VTE treatment Phase III
RE-COVER [22] Parenteral 
anticoagulant/warfarin 
(2564)
RE-COVER II [23] Parenteral 
anticoagulant/warfarin 
(2589)
RE-SONATE [24] Placebo (1353)
RE-MEDY [24] Warfarin (2866)
Stroke prevention  
in atrial fibrillation
Phase II
PETRO [25] Aspirin or warfarin (502)
Phase III
RE-LY [26] Warfarin (18,000)
RELY- ABLE [27] Placebo (5851)
Acute coronary 
syndrome
RE-DEEM [28] Placebo (1878)
Percutaneous 
coronary 
intervention
D-fine [29] Heparin (50)
Data from [16–29]
VTE venous thromboembolism
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with 50 mg bid but elevated with higher doses, nearly achiev-
ing statistical significance with the 300 mg qd dose (P = 0.051). 
Together, the BISTRO I and BISTRO II trials showed that 
dabigatran etexilate might be an effective and safe anticoagu-
lant and served as a basis for dose justification in phase III 
trials.
The clinical utility of dabigatran etexilate for the preven-
tion of VTE in patients after major joint surgery was con-
firmed in three large randomized, double-blind, multicenter 
trials (Table 2.3) [18–21]. The RE-MODEL trial [18] com-
pared dabigatran etexilate (150 mg or 220 mg qd, starting 
with a half-dose 1–4 h after TKR) and enoxaparin (40 mg qd 
starting the evening before surgery in 2076 patients). The 
treatment continued for 6–10 days and patients were fol-
lowed up for 3 months. The primary efficacy outcome of a 
composite of total VTE (venographic or symptomatic) and 
mortality during treatment occurred in 37.7 % of patients in 
the enoxaparin group, 36.4 % of the dabigatran etexilate 
220 mg group and 40.5 % of the 150 mg dabigatran etexilate 
group. Both dabigatran etexilate doses proved to be non- 
inferior to enoxaparin. The incidence of major hemorrhage 
also did not differ significantly across the three groups 
(1.3 %, 1.5 %, and 1.3 %, respectively).
A similar design was used in the RE-NOVATE trial [19] to 
test potential non-inferiority of dabigatran etexilate for VTE 
prophylaxis in 3494 patients undergoing THR, except that the 
treatment was continued for 28–35 days. The primary efficacy 
outcome, a composite of total VTE and all-cause mortality 
during treatment, occurred in 6.7 % of individuals in the 
enoxaparin group, 6.0 % of patients in the dabigatran etexi-
late 220 mg qd group, and 8.6 % of patients in the 150 mg qd 
group; that is, both the dabigatran etexilate doses were non- 
inferior to enoxaparin. There was no significant difference in 
major hemorrhage rates with either dose of dabigatran etexi-
late compared with enoxaparin. In the phase III RE-NOVATE 
II trial, the efficacy and safety of oral dabigatran versus sub-
cutaneous enoxaparin was compared for extended thrombo-
prophylaxis in patients undergoing total hip arthroplasty. 
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A total of 2055 patients were randomized. The primary effi-
cacy outcome was a composite of total VTE and death from 
all causes. The main secondary composite outcome was major 
VTE plus VTE-related death. The main safety endpoint was 
major bleeding. The primary efficacy outcome occurred in 
7.7 % of the dabigatran group versus 8.8 % of the enoxaparin 
group (P < 0.0001 for the pre-specified non-inferiority mar-
gin). Major VTE plus VTE-related death occurred in 2.2 % 
of the dabigatran group versus 4.2 % of the enoxaparin 
group. Major bleeding events did not differ between the two 
arms [21].
No significant differences in the incidences of liver enzyme 
elevation and acute coronary events were observed during 
treatment or follow-up in the RE-MODEL or the 
RE-NOVATE I and II trials.
The successful record of dabigatran etexilate in preceding 
clinical trials was partly compromised in the double-blind, 
centrally randomized RE-MOBILIZE trial [20], in which the 
North American recommended dose for VTE prophylaxis 
was used for the enoxaparin comparator (i.e., 30 mg bid 
rather than 40 mg qd). Dabigatran etexilate 220 or 150 mg qd 
was compared with enoxaparin 30 mg bid after knee arthro-
plasty surgery. Among 1896 patients, dabigatran etexilate at 
both doses showed inferior efficacy to enoxaparin, with VTE 
rates of 31 % for 220 mg qd (P = 0.02 versus enoxaparin), 
34 % for 150 mg qd (P < 0.001 versus enoxaparin), and 25 % 
for enoxaparin. Major hemorrhage was uncommon in all 
groups: 0.6 % for dabigatran 220 mg qd, 0.6 % for dabigatran 
150 mg qd, and 1.4 % for enoxaparin (no significant differ-
ences). Serious adverse events occurred in 6.9 % of dabiga-
tran 220 mg qd patients, 6.5 % of dabigatran 150 mg qd 
patients, and 5.2 % of enoxaparin patients.
An interesting clinical difference between European and 
North American prophylactic dosing regimens for antithrom-
botic drugs for perioperative orthopedic patients is that, his-
torically, European dosing regimens administered these 
drugs before surgery, whereas in North America dosing 
began postoperatively, sometimes at a higher total daily 
2.2 Dabigatran Etexilate
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 dosage [30]. Because dabigatran was first investigated in 
European joint arthroplasty patients, the LMWH control 
therapy, enoxaparin, was initiated the evening before the day 
of surgery at the standard dosage of 40 mg qd in the phase II 
studies.
In March 2008, the European Commission granted mar-
keting authorization for dabigatran etexilate for the preven-
tion of VTE in adults who have undergone THR or TKR. The 
drug was launched in the UK in April 2008.
A number of observational cohort studies aimed to further 
optimize clinical management with dabigatran in VTE follow-
ing joint surgery by selecting specific patient groups and treat-
ment regimens. A recently completed study (ClinicalTrials.gov 
Identifier NCT00846807) [31] investigated the safety and 
efficacy of dabigatran 220 mg in patients with an increased 
risk of bleeding or VTE and an ongoing study (ClinicalTrials.
gov Identifier NCT00847301) [32] evaluating the safety and 
efficacy of dabigatran 150 mg in patients with renal impair-
ment has been recently completed and its results are awaited.
2.2.2  Venous Thromboembolism Treatment
The promising efficacy results for dabigatran in the preven-
tion of thromboembolic disorders following major joint sur-
gery prompted the developers to test the drug’s utility in 
VTE treatment (Table 2.2) [16–27].
The RE-COVER study was a randomized, double-blind, 
non-inferiority trial involving 1274 patients with acute VTE 
who were initially given parenteral anticoagulation therapy 
for a median of 9 days [22]. The RE-COVER population was 
assigned to dabigatran, administered at a dose of 150 mg bid, 
or dose-adjusted warfarin. The primary outcome was the 
6-month incidence of recurrent VTE and related deaths. 
Safety endpoints included bleeding events, acute coronary 
syndrome (ACS) events, other adverse events, and results of 
liver-function tests. The RE-COVER investigators concluded 
that for the treatment of acute VTE, a fixed dose of 
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 dabigatran is as effective as warfarin (primary outcome rate 
2.4 % versus 2.1 %, respectively; P < 0.001 for the pre-speci-
fied non- inferiority margin) and has a safety profile that is 
similar to that of warfarin (Table 2.4) [22]. Based on the suc-
cess of RE-COVER, RE-COVER II was initiated to confirm 
the low rate of recurrent VTE observed. RE-COVER II was 
a 6-month, double-blind, randomized trial comparing treat-
ment with dabigatran to warfarin in 2589 VTE patients 
(either acute symptomatic proximal DVT or pulmonary 
embolism). Patients were randomized to dabigatran 150 mg 
bid or dose-adjusted warfarin (INR 2.0–3.0). The primary 
efficacy and safety outcomes were the same as those used in 
RE-COVER. RE-COVER II confirmed the non-inferiority 
of dabigatran (primary outcome occurred in 2.3 % of patients 
treated with dabigatran vs 2.2 % of patients treated with war-
farin; P < 0.001) (Table 2.4). Additionally, RE-COVER II 
Table 2.4 Efficacy and safety of dabigatran etexilate in phase III 
VTE trials
Dabigatran Comparator
Duration  
of treatment 
(months)
VTE and 
all- cause 
mortality 
n/N (%)
Major 
hemorrhage 
n/N (%)
VTE and 
all- cause 
mortality 
n/N (%)
Major 
hemorrhage 
n/N (%)
RE-COVER 
[22]
n = 2564
6 30/1274 
(2.4)
20/1274 
(1.6)
27/1265 
(2.1)
24/1265  
(1.9)
RE-COVER 
II [23]
n = 2589
6 30/1279 
(2.3)
15/1279 
(1.2)
28/1289 
(2.2)
22/1289  
(1.7)
RE-MEDY  
[24]
n = 2866
6–36 26/1430 
(1.8)
13/1430 
(0.9)
18/1426 
(1.3)
25/1426  
(1.8)
RE-SONATE 
[24]
n = 1353
6–18 3/681  
(0.4)
2/681  
(0.3)
37/662 
(5.6)
0/0 (0.0)
Data from [22–24]
VTE venous thromboembolism
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confirmed the superiority of dabigatran for clinically relevant 
non-major (CRNM) bleeding and for any bleeding [23].
In a separate phase III randomized multicenter trial, 
RE-SONATE, the efficacy of prolonged (additional 
12 months) administration of dabigatran etexilate in 1547 
patients with VTE was compared with placebo. In 
RE-SONATE, extended treatment with dabigatran was asso-
ciated with a 92 % relative risk reduction for recurrent VTE 
and a low risk for major bleeding [24]. Additionally, the 
RE-MEDY trial evaluated the comparative safety and effi-
cacy of dabigatran etexilate and warfarin for the long-term 
treatment and secondary prevention of symptomatic VTE in 
2866 patients already successfully treated with a standard 
anticoagulant approach for 3–6 months for confirmed acute 
symptomatic VTE. In RE-MEDY, dabigatran demonstrated 
non-inferiority to warfarin for the outcome of recurrent VTE 
(primary outcome rate 1.8 % vs 1.3 % respectively; P = 0.01 
for non-inferiority), with fewer bleeds (19.4 % vs 26.2 %, 
respectively; P < 0.001), but there were more ACS events in 
the dabigatran group than in those taking warfarin (0.9 % vs 
0.2 %; P = 0.02) (Table 2.4) [24].
2.2.3  Stroke Prevention in Atrial Fibrillation
The clinical safety of dabigatran etexilate (with or without 
aspirin) in patients with atrial fibrillation (AF) was first 
assessed in the phase II dose-range Prevention of Embolic 
and ThROmbotic Events in Patients with Persistent Atrial 
Fibrillation (PETRO) trial [25]. In this trial, 502 patients with 
AF were randomized to receive dabigatran etexilate 50, 150, 
or 300 mg bid alone or combined with 81 mg or 325 mg of 
aspirin or warfarin qd for 12 weeks. Major hemorrhage was 
limited to the group treated with 300 mg dabigatran plus 
aspirin (4 of 64), and the incidence was significant versus 
300 mg dabigatran alone (0 of 105, P < 0.02). Total hemor-
rhage events were more frequent in the 300 mg (23 %) and 
150 mg (18 %) dabigatran groups compared with the 50 mg 
Chapter 2. Direct Thrombin Inhibitors
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groups (7 %; P = 0.0002 and P = 0.01, respectively). The study 
demonstrated that major hemorrhages were limited to 
patients treated with dabigatran 300 mg plus aspirin, and 
thromboembolic episodes were limited to the 50 mg dabiga-
tran groups. On the basis of the PETRO study, 150 and 
220 mg doses were chosen for further development in phase 
III studies of stroke prevention in AF.
The Randomized Evaluation of Long term anticoagu-
lant therapy (RE-LY) with dabigatran etexilate trial com-
pared the efficacy and safety of two doses of dabigatran 
etexilate with warfarin in over 18,000 patients with AF with 
an average age of 71 years. The primary outcome measure 
was the incidence of stroke (including hemorrhagic) or sys-
temic embolism at the median 2-year follow-up period. 
Treatment with the higher, 150 mg bid dose significantly 
reduced the rate of stroke and systemic embolism (with a 
relative risk of 0.66, P < 0.001; the rate of hemorrhagic 
stroke was 0.38 % per year in the warfarin group versus 
0.10 % per year with dabigatran, P < 0.001), with a similar 
overall risk to warfarin for major bleeding [26]. The lower, 
110 mg bid dose resulted in a similar risk for stroke as war-
farin but with a significantly reduced major bleeding event 
rate (20 % relative risk reduction, 3.36 % per year in the 
warfarin group versus 2.71 % per year with dabigatran, 
P = 0.003). The rate of hemorrhagic stroke was 0.38 % per 
year in the warfarin group, as compared with 0.12 % 
per year with 110 mg dabigatran (P < 0.001) and 0.10 % per 
year with 150 mg of dabigatran (P < 0.001). Annual mortal-
ity rate was 4.13 % in the warfarin group, 3.75 % with 
110 mg of dabigatran and 3.64 % with 150 mg of dabigatran 
(borderline significance, P = 0.051) [26] (Fig. 2.2). The long-
term extension study, RELY-ABLE, investigated the safety 
of prolonged treatment with dabigatran etexilate; 5851 
patients who completed dabigatran treatment in the RE-LY 
study were enrolled into RELY-ABLE to continue with the 
two effective doses of dabigatran (110 and 150 mg). Primary 
outcomes for RELY-ABLE were the same as those for 
RE-LY. For both doses studied, the rates of major ischemic, 
2.2 Dabigatran Etexilate
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hemorrhagic and fatal outcomes were consistent with those 
seen in RE-LY, demonstrating the safety of both doses in 
long-term treatment. RELY-ABLE did not show any 
 significant differences between the two doses in the rate of 
stroke (1.46 %/year for 150 mg vs 1.60 %/year for 110 mg) 
or mortality (3.02 %/year for 150 mg vs 3.10 %/year for 
110 mg), however there was a higher rate of bleeding in the 
150 mg patient group (3.74 %/year vs 2.99 %/year) [27].
In view of the results of the RE-LY trial, dabigatran has 
been included in the latest European guidelines for man-
agement of AF as an alternative to VKAs for primary or 
secondary prevention of stroke in patients with AF. In 
October 2010 the United States (US) FDA approved the 
150 mg bid dosage, which should be reduced to 75 mg bid in 
selected cases (e.g., creatinine clearance 15–30 mL/min). 
Dabigatran is licensed by the European Medicines Agency 
(EMA) at two dosages (110 mg and 150 mg bid), depending 
on the balance between thromboembolic and bleeding risk 
factors.
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Figure 2.2 Cumulative hazard rates for the primary outcome of 
stroke or systemic embolism, according to treatment group 
(Reproduced with permission from Connolly et al. [26])
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2.2.4  Other Directions
The potential application of DTIs is not limited to conditions 
related to venous thrombosis, and dabigatran etexilate has 
also been tested in phase II trials in clinical settings of arterial 
thrombosis. In the phase II, randomized, open-label D-fine 
study of dabigatran etexilate in elective percutaneous coro-
nary intervention (PCI) two doses of dabigatran etexilate 
(110 mg and 150 mg bid) were compared with heparin (both 
in addition to a standard dual antiplatelet regimen) in 50 
patients undergoing elective PCI. The results of this study 
suggested that treatment with dabigatran (both 110 and 
150 mg) may not provide sufficient anticoagulation during 
PCI [29]. RE-DEEM (Dose-Finding Study for Dabigatran 
Etexilate in Patients With Acute Coronary Syndrome), a 
larger (n = 1878) placebo-controlled trial, evaluated the safety 
and potential efficacy of four different dabigatran doses 
administered twice daily for 6 months in addition to dual 
antiplatelet treatment in patients with ACS at high risk of 
cardiovascular complications [28]. In the RE-DEEM study 
dabigatran, in addition to dual antiplatelet therapy, was asso-
ciated with a dose-dependent increase in bleeding events 
compared with placebo and significantly reduced coagulation 
activity in patients with a recent myocardial infarction [28].
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